Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Spiramycin]

V Vacek1

  • 12. infekcní klinika 3. LFUK a FN, Praha-Bulovka.

Casopis Lekaru Ceskych
|January 17, 1994
PubMed
Summary
This summary is machine-generated.

Spiramycin is a macrolide antibiotic effective against various bacteria, including Gram-positive and some Gram-negative strains. Its tissue affinity and favorable tolerance make it a valuable therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same journal

The personality of professor Otakar Štark in the context of the development of medical genetics in Czechoslovakia in the years 1950-1990.

Casopis lekaru ceskych·2026
Same journal

Václav Náprstek, MD - a forgotten hero.

Casopis lekaru ceskych·2026
Same journal

Professor Otto Piffl, the First Full Professor of Otology and Rhinology at the German University in Prague, passed away 100 years ago.

Casopis lekaru ceskych·2026
Same journal

Ancient sanctuary of Eileithyia, goddess of childbirth, on the island of Paros (Greece).

Casopis lekaru ceskych·2026
Same journal

European Partnership for Personalised Medicine (EP PerMed).

Casopis lekaru ceskych·2026
Same journal

Periodontitis and type 2 diabetes.

Casopis lekaru ceskych·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology

Context:

  • Spiramycin, a 16-membered macrolide antibiotic, has been in clinical use since 1955.
  • It functions by inhibiting bacterial protein synthesis during translocation.

Purpose:

  • To detail the antibacterial spectrum, mechanisms of action, and clinical utility of spiramycin.
  • To compare spiramycin's in vitro and in vivo efficacy with erythromycin.

Summary:

  • Spiramycin exhibits bacteriostatic action, with bactericidal effects on highly sensitive strains.
  • Its antibacterial spectrum includes Gram-positive cocci/rods, Gram-negative cocci, Legionella, Mycoplasma, Chlamydia, and Toxoplasma gondii.
  • Resistance mechanisms exist and correlate with prescription frequency.

Impact:

Related Experiment Videos

  • Spiramycin achieves high tissue concentrations, exceeding serum levels, due to its great affinity.
  • Favorable tissue distribution, slow release, action in sub-inhibitory concentrations, and a long post-antibiotic effect contribute to its in vivo effectiveness.
  • The antibiotic is well-tolerated, with exceptionally favorable gastrointestinal and general tolerance.